Sirolimus is a new immunosuppressive drug used to avoid allograft rejection. The immunosuppressive effect of sirolimus is due to inhibition of the mammalian target of rapamycin, necessary for the proliferation and clonal expansion of activated T-cells. Because T-cells play a central role in the pathogenesis of autoimmune disease developed in (NZB×NZW)F1 mice, we evaluated the therapeutic use of sirolimus in such mice. (NZB×NZW)F1 female mice received 1mg/kg/day of sirolimus from 12 to 37 weeks of age. The development of autoimmune disease was evaluated by measuring the serum levels of auto-antibodies (autoAbs) and their immunoglobulin isotypes, prevalence of glomerulonephritis and mortality rates. Sirolimus directly inhibited production of autoAbs, glomerular deposits of immunoglobulins and development of proteinuria; also the survival of these mice was prolonged. Our results demonstrate the beneficial effects of sirolimus in preventing the development of lupus disease in (NZB×NZW)F1 female mice. Lupus (2007) 16, 775—781.
Santiago ML, Fossati L., Jacquet C., Muller W., Izui S., Reininger L.Interleukin-4 protect against a genetically linked lupus-liked autoimmune syndrome. J Exp Med1997; 185: 65—70.
2.
Ravetch JV, Bolland S.IgG Fc receptors. Annu Rev Immunol2001; 19: 275—290.
3.
Abraham RT, Wiederrecht GJImmunopharmacology of rapamycin. Annu Rev Immunol1996; 14: 483—510.
4.
Blaha P., Bigenzahn S., Koporc Z. et al. The influence of immunosuppressive drugs on tolerance induction through bone marrow transplantation with costimulation blockade. Blood2003; 101: 2886—2893.
5.
Battaglia M. , Stabilini A., Roncarolo MGRapamycin selectively expands CD4+CD25+FOXP3+ regulatory cells. Blood2005; 105: 4743—4748.
6.
Kim HS, Raskova J., Degiannis D., Risk KJEffects of cyclosporin and rapamycin on immunoglobulin production by preactivated human B cells. Clin Exp Immunol1994; 96: 508—512.
7.
Ferraresso M. , Tian L., Ghobrial R., Stepkowski SM, Kahan BDRapamaycin inhibits production of cytotoxic but not noncytotoxic antibodies and preferentially activates T helper 2 cells that mediate long-term survival of heart allografts in rats. J Immunol1994; 153: 3307—3318.
8.
Saunders RN, Metcalfe MS, Nicholson MLRapamycin in transplantation: a review of the evidence. Kidney Int2001; 59: 3—16.
9.
Ruiz JC, Campistol JM, Grinyo JM et al. Early cyclosporine a withdrawal in kidney-transplant recipients receiving sirolimus prevents progression of chronic pathologic allograft lesions . Transplantation2004; 78: 1312—1318.
10.
Morice MC, Serruys PW, Sousa JE et al. RAVEL Study Group. Randomized Study with the sirolimus-coated Bx velocity balloon-expandable stent in the treatment of patients with de novo native coronary artery lesions. N Engl J Med2002; 343: 1773—1780.
11.
Liu M., Howes A., Lesperance J. et al. Antitumor activity of rapamycin in a transgenic mouse model of ErbB2-dependent human breast cancer. Cancer Res2005; 65: 5325—5336.
12.
Reitamo S., Spuls P., Sassolas B., Lahfa M., Claudy A., Griffiths CE, Sirolimus European Psoriasis Study Group. Efficacy of sirolimus (rapamycin) administered concomitanly with a subtherapeutic dose of cyclosporin in the treatment of severe psoriasis randomized controlled trial. Br J Dermatol2001; 145: 438—445.
13.
Carlson RP, Hartman DA, Tomchek LA et al. Rapamycin, a potential disease-modifying antiarthritic drug . J Pharmacol Exp Ther1993; 266: 1125—1138.
14.
Warner LM, Adams LM, Sehgal SNRapamycin prolongs survival and arrests pathophysiologic changes in murine systemic lupus erythematosus. Arthritis Rheum1994; 37: 289—297.
15.
Ramos MA, Piñera C., Setien MA et al. Modulation of autoantibody production by mycophenolate mofetil: effects on the development of SLE in (NZB/W)F1 mice. Nephrol Dial Transplant2003; 18: 878—883.
16.
Groth CG, Backman L., Morales JM, Calne R., Kreis H., Lang P., Touraine JL, Claesson K., Campistol JM, Durand D., Wramner L., Brattstrom C., Charpentier B.Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group. Transplantation1999; 67: 1036—1042.
17.
Bonegio RG, Fuhro R., Wang Z. et al. Rapamycin ameliorates proteinuria-associated tubulointerstitial inflammation and fibrosis in experimental membranous nephropathy. J Am Soc Nephrol2005; 16: 2063—2072.
18.
Morelon E., Mamzer-Bruneel MF, Peraldi MN, Kreis H.Sirolimus: a new promising immunosuppressive drug. Towards a rationale for its use in renal transplantation. Nephrol Dial Transplant2001; 16: 18—20.
19.
Fervenza FC , Fitzpatric PM, Mertz J. et al. Acute rapamycin nephrotoxicity in native kidneys of patients with chronic glomerulopathies . Nephrol Dial Transplant2004; 19: 1288—1292.
20.
Ruiz JC, Campistol JM, Sánchez-Fructuoso A. et al. Increase of proteinuria after conversion from calcineurin inhibitor to sirolimus-based treatment in kidney transplant patients with chronic allograft dysfunction. Nephrol Dial Transplant2006; 11: 3252—3257.
21.
Coppo R., Amore A.New perspectives in treatment of glomerulonephritis. Pediatr Nephrol2004; 19: 256—265.
22.
Fernandez D. , Bonilla E., Mirza N., Niland B., Perl A.Rapamycin reduces disease activity and normalizes T cell activation — induced calcium fluxing in patients with systemic lupus erithematosus. Arthritis Rheum2006; 54: 2983—2988.
23.
Early G., Zhao W., Burns C.Anti-CD40 ligand antibody treatment prevents the development of lupus-like nephritis in a subset of New Zealand white mice. Response correlates with the absence of an anti-body response. J Immunol1996; 157: 3159—3164.
